WINSTON-SALEM – Javara, a clinical research services firm that is actively involved in the fight against the COVID-19 pandemic with multiple partners, has raised $4.6 million in new capital.
Eleven investors are backing Javara, according to a securities filing.
The new cash follows a funder that produced $3.775 million in August of last year.
Javara earlier this month announced its partnership with Wake Forest Baptist Health to begin recruiting patients for a COVID-19 vaccine trial.
More about Javara
Javara CEO aims to improve patient participation in clinical trials
